JP2022527646A - 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法 - Google Patents

抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法 Download PDF

Info

Publication number
JP2022527646A
JP2022527646A JP2021560416A JP2021560416A JP2022527646A JP 2022527646 A JP2022527646 A JP 2022527646A JP 2021560416 A JP2021560416 A JP 2021560416A JP 2021560416 A JP2021560416 A JP 2021560416A JP 2022527646 A JP2022527646 A JP 2022527646A
Authority
JP
Japan
Prior art keywords
antibody
dectin
cells
phagocytosis
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021560416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527646A5 (enExample
Inventor
パナギオティス フォタキス，
シャンティ マリアテギュ チャン，
ルオ シ シ，
アダム ルイス セイルズ，
ネナド トマセヴィック，
Original Assignee
ドレン バイオ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドレン バイオ， インコーポレイテッド filed Critical ドレン バイオ， インコーポレイテッド
Publication of JP2022527646A publication Critical patent/JP2022527646A/ja
Publication of JP2022527646A5 publication Critical patent/JP2022527646A5/ja
Priority to JP2025060435A priority Critical patent/JP2025096316A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2021560416A 2019-04-05 2020-04-03 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法 Withdrawn JP2022527646A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025060435A JP2025096316A (ja) 2019-04-05 2025-04-01 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962830139P 2019-04-05 2019-04-05
US62/830,139 2019-04-05
PCT/US2020/026721 WO2020206354A1 (en) 2019-04-05 2020-04-03 Methods of depleting disease causing agents via antibody targeted phagocytosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025060435A Division JP2025096316A (ja) 2019-04-05 2025-04-01 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法

Publications (2)

Publication Number Publication Date
JP2022527646A true JP2022527646A (ja) 2022-06-02
JP2022527646A5 JP2022527646A5 (enExample) 2023-04-06

Family

ID=72667025

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021560416A Withdrawn JP2022527646A (ja) 2019-04-05 2020-04-03 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法
JP2025060435A Pending JP2025096316A (ja) 2019-04-05 2025-04-01 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025060435A Pending JP2025096316A (ja) 2019-04-05 2025-04-01 抗体によって標的化されたファゴサイトーシスにより疾患原因物質を枯渇させる方法

Country Status (12)

Country Link
US (2) US20220169737A1 (enExample)
EP (1) EP3947467A4 (enExample)
JP (2) JP2022527646A (enExample)
KR (1) KR20220031995A (enExample)
CN (1) CN114502585A (enExample)
AU (1) AU2020253621A1 (enExample)
BR (1) BR112021019950A2 (enExample)
CA (1) CA3136272A1 (enExample)
IL (1) IL286967A (enExample)
MX (1) MX2021012035A (enExample)
SG (1) SG11202110663UA (enExample)
WO (1) WO2020206354A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102590454B1 (ko) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
WO2021222894A1 (en) 2020-05-01 2021-11-04 Bolt Biotherapeutics, Inc. Anti-dectin-2 antibodies
MX2023004054A (es) 2020-10-07 2023-06-29 Dren Bio Inc Anticuerpos anti-dectina 1 y metodos de uso de los mismos.
CN119301156A (zh) * 2022-04-04 2025-01-10 德伦生物公司 抗Dectin-1抗体和其使用方法
US20250223364A1 (en) * 2022-04-04 2025-07-10 Dren Bio, Inc. Multispecific binding proteins that bind dectin-1 and cd20 and methods of use thereof
KR20260048578A (ko) * 2023-07-31 2026-04-10 드렌 바이오 매니지먼트, 인크. Dectin-1 및 TROP-2에 결합하는 다중특이적 결합 단백질 및 이의 사용 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519316A (ja) * 2007-02-23 2010-06-03 ベイラー リサーチ インスティテュート デクチン−１を介したヒト抗原提示細胞の活性化の治療への応用
WO2018176159A1 (en) * 2017-03-31 2018-10-04 Zymeworks Inc. Tumor antigen presentation inducer constructs and uses thereof
WO2020023920A1 (en) * 2018-07-27 2020-01-30 Alector Llc Anti-siglec-5 antibodies and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129227A1 (en) * 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
US12384850B2 (en) * 2017-06-25 2025-08-12 Systimmune, Inc. Guidance and navigation control proteins and method of making and using thereof
CA3106796A1 (en) * 2018-07-19 2020-01-23 Oncohost Ltd Il-31 improves efficacy of macrophage-based adoptive cell therapy for cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519316A (ja) * 2007-02-23 2010-06-03 ベイラー リサーチ インスティテュート デクチン−１を介したヒト抗原提示細胞の活性化の治療への応用
WO2018176159A1 (en) * 2017-03-31 2018-10-04 Zymeworks Inc. Tumor antigen presentation inducer constructs and uses thereof
WO2020023920A1 (en) * 2018-07-27 2020-01-30 Alector Llc Anti-siglec-5 antibodies and methods of use thereof

Also Published As

Publication number Publication date
US20250206826A1 (en) 2025-06-26
BR112021019950A2 (pt) 2021-12-07
US20220169737A1 (en) 2022-06-02
SG11202110663UA (en) 2021-10-28
MX2021012035A (es) 2022-03-11
AU2020253621A1 (en) 2021-11-11
CA3136272A1 (en) 2020-10-08
CN114502585A (zh) 2022-05-13
EP3947467A4 (en) 2023-01-04
KR20220031995A (ko) 2022-03-15
IL286967A (en) 2021-12-01
JP2025096316A (ja) 2025-06-26
WO2020206354A1 (en) 2020-10-08
EP3947467A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
US20250206826A1 (en) Methods of depleting disease causing agents via antibody targeted phagocytosis
JP7803942B2 (ja) 抗デクチン－１抗体及びその使用方法
WO2021259199A1 (zh) 抗cd73抗体及其用途
US20110262461A1 (en) Biological materials and uses thereof
CN116801889A (zh) 包含具有多特异性抗体的离体武装t细胞的组合物和其用途
KR20250006353A (ko) 항-덱틴-1 항체 및 이의 사용 방법
JPWO2015034052A1 (ja) ヒトインテグリンａ６ｂ４と特異的に反応する抗体
JP2025511389A (ja) デクチン－１及びｃｄ２０に結合する多重特異性結合タンパク質ならびにその使用方法
TW202144420A (zh) 一種免疫細胞啟動劑的開發及應用
CA3140210A1 (en) Sodium fluorescein as a reversal agent for an anti-fluorescein car t cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers
CN116178545B (zh) 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
JP2022525937A (ja) Ｂｔｎ２に対する特異性を有する抗体及びその使用
Kim et al. Engineering bispecific T-cell engagers to deplete eosinophils for the treatment of severe eosinophilic asthma
EP4506368A1 (en) Bispecific antibody to human tim-3 and human cd39, and applications thereof
JP2026508791A (ja) 免疫療法の有効性及び永続的奏効の改善
US20190256592A1 (en) Binding agents for use in therapy
CN116724054A (zh) 抗Dectin-1抗体和其使用方法
HK40101749A (zh) 抗dectin-1抗体和其使用方法
HK1167668A (en) Anti-icam1 antibodies for inducing apoptosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250401

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250613